ArticleCancer medicine2025
Risk Factors Influencing Survival in T-Cell Lymphoblastic Lymphoma and T-Cell Acute Lymphoblastic Leukemia.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Flow Cytometry-Guided Diagnosis of Cortical T-Lymphoblastic Lymphoma Presenting With a Massive Mediastinal Mass and Borderline Bone Marrow Involvement.Journal of clinical laboratory analysis · 2026Article
- Risk Factors Influencing Survival in T-Cell Lymphoblastic Lymphoma and T-Cell Acute Lymphoblastic Leukemia.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundT-cell lymphoblastic lymphoma (T-LBL) is a rare non-Hodgkin lymphoma. The World Health Organization defines T-LBL and T-cell acute lymphoblastic leukemia (T-ALL) as the same entity. However, the clinical variations between them result in divergent treatment outcomes.
objectivesThe aim of this study was to compare the outcomes of patients with T-LBL and T-ALL and identify ideal candidates for autologous hematopoietic stem cell transplantation (auto-HSCT) or allogeneic hematopoietic stem cell transplantation (allo-HSCT). STUDY
designThis retrospective analysis included 148 patients diagnosed with T-LBL (67 [45.3%]) or T-ALL (81 [54.7%]) between November 2009 and December 2022 in seven hospitals in the Republic of Korea. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method, and allo-HSCT, auto-HSCT, and chemotherapy-only treatment modalities were compared. Cox proportional hazards models were used to identify risk factors for survival, and survival decision trees were used for risk stratification.
resultsThe median follow-up duration was 60 months. The 5-year OS rates were 43.5% and 52.8% in the T-LBL and T-ALL groups, respectively (p = 0.111). The T-LBL group had lower PFS than the T-ALL group (p < 0.001). The 5-year OS rates for allo-HSCT, auto-HSCT, and chemotherapy-only were 62.8%, 62.4%, and 13%, respectively. Two or more extranodal sites, large masses > 6 cm, axial bone involvement, and non-complete remission after chemotherapy were poor prognostic factors for OS.
conclusionsIn this multicenter retrospective analysis, hematopoietic stem-cell transplantation (allo- or auto-HSCT) was associated with better survival than chemotherapy alone. For T-LBL, an exploratory signal from our prognostic model suggests that selected high-risk patients may be considered for upfront allo-HSCT. However, overall survival was comparable between allo- and auto-HSCT in this cohort, and durable outcomes after transplant were largely observed in patients who achieved complete remission. These findings are hypothesis-generating and support individualized, response-adapted strategies that warrant prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.